Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From Underweight - Here's Why

Novo Nordisk A/S (NYSE:NVO) is one of the best undervalued stocks to invest in right now.

Novo Nordisk A/S (NYSE:NVO) was upgraded to Equal Weight from Underweight by Morgan Stanley on March 3. The firm also adjusted the price target on the stock to $40 from $42, stating that the stock’s valuation post the selloff on the REDEFINE-4 data better reflects its mid-term growth uncertainty and the loss of exclusivity risks on semaglutide. It further told investors in a research note that consensus estimates have been rebased.

In a separate development, Novo Nordisk A/S (NYSE:NVO) announced on February 27 that the US Food and Drug Administration approved three new indications for once-weekly Sogroya injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone, for children aged at least 2.5 years with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age without catch-up growth by the age of 2 years, and growth failure associated with Noonan Syndrome.

The approval marks the first long-acting growth hormone supporting children with these three indications in the United States. Somapacitan-beco also holds approval for children aged at least 2.5 years with growth hormone deficiency. Since the option is once-weekly, it helps children and caregivers struggling with daily injections for hormone treatment.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.